Panacea Biotec — 360° view

Panacea Biotec, a company in the Pharmaceuticals industry, reported revenue of ₹190 crore and net profit of ₹12 crore for the September 2026 quarter.

Panacea Biotec (NSE: PANACEABIO) closed at ₹335.95 on 20 Nov 2026, down 5.8% over the past year. Its market capitalisation is ₹2,058 crore and it trades at 190.4 times earnings.

Share price
₹335.95 (20 Nov 2026)
Market cap
₹2,058 Cr (20 Nov 2026)
P/E
190.37 (20 Nov 2026)
Revenue
₹190 Cr (September 2026 quarter)
Net profit
₹12 Cr (September 2026 quarter)
ROCE
-2.43% (FY26)
ROE
-2.42% (FY26)
Book value
₹139 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹647.00 / ₹292.40 (20 Nov 2026)
1-year return
-5.8% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: PANACEABIO

Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.